Sight Sciences is an ophthalmic medical device company engaged in the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Co.'s surgical glaucoma product portfolio features the OMNI Surgical System, a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. Co.'s nonsurgical dry eye product portfolio consists of the TearCare system for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids. The SGHT stock yearly return is shown above.
The yearly return on the SGHT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SGHT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|